Dose tapering and early discontinuation to increase cost-effectiveness of immunotherapy trial number 1

Dose tapering and early discontinuation to increase cost-effectiveness of immunotherapy trial number 1 - Dedication-1 NVALT30

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON54321

Enrollment

750

Registered

2020-05-26

Start date

2020-11-18

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Reduced dose versus standard dose

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Eligible for treatment of non-small cell lung cancer with pembrolizumab in line with the current ESMO treatment guidelines

Exclusion criteria

Exclusion criteria: Not willing to give informed consent

Design outcomes

Primary

Measure	Time frame
1-year survival	—

Secondary

Measure	Time frame
Biomarker performance to predict treatment response	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)